about
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study.Rheumatology education and management skills in general practice: a national study of traineesAssessing progression of patellofemoral osteoarthritis: a comparison between two radiographic methodsLupus nephritis: a 15-year multi-centre experience in the UK.Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studiesRheumatology: what should all doctors know?Characterisation of size and direction of osteophyte in knee osteoarthritis: a radiographic studyA Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome.Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome - Capturing the discrepancy.Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome.The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012.Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokinesSensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus.Assessment of a genetic contribution to osteoarthritis of the hip: sibling study.Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome.Early Clinical Features in Systemic Lupus Erythematosus: Can They Be Used to Achieve Earlier Diagnosis? A Risk Prediction Model.Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink.Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012.The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.Lessons learnt in the management of Wegener's Granulomatosis: long-term follow-up of 60 patients.The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population.Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012.Epidemiology of peripheral joint osteoarthritis.Cladribine in the treatment of systemic lupus erythematosus nephritis.Health-related utility values of patients with primary Sjögren's syndrome and its predictors.Assessment of Be1 and Be2 cells in systemic lupus erythematosus indicates elevated interleukin-10 producing CD5+ B cells.Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study.Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy.Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis.Can granulomatosis with polyangiitis be diagnosed earlier in primary care? A case-control study.Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies.Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide.
P50
Q33517066-677416A7-753C-4132-A87E-F81C2C9A8B1CQ33578335-C88FA13C-F083-45A8-852E-199D862ACF23Q33579497-9052E766-39A6-4DC5-8FC0-730A77E4CAEDQ34578139-31587AFE-650C-4885-80E3-B338952CF0DAQ35204001-49EC2AAB-2197-4961-8870-536EE056C4F7Q35549363-87E0937B-EF5F-412D-B305-BB2DBABE17C8Q35551445-BF53FC26-B6D8-4007-8873-F1120594EA48Q35875673-38B00142-D904-40A2-BC40-666DBF304390Q36228694-78310F7C-1238-4BDE-9440-E2AAF917D6EBQ36370494-81B7D811-C72E-4BFA-8046-B34A31A87C99Q36475637-BBCB5818-3AB0-41C5-B027-97758FDC67E9Q37133826-C46E7BE1-73B3-4E78-943F-C6DBC4754BA2Q37316490-D15B1F3F-3234-402D-9C52-E2A27B031549Q37362870-59047D85-3C0D-46EF-9757-64828FB52AD2Q37709971-4EF9DE12-571B-4A1A-B8EE-5D69D4DE31FFQ38824959-58FF6673-5C91-4F19-896D-DDC22F357F9AQ38906337-215E36DA-4C78-4F7F-8904-FD0767AB0B3AQ39066343-0E2F5235-3DA9-4BF0-A95B-62994C3F9A82Q39819362-A047FCAD-2919-46E7-B438-4C2A0F1D6A90Q40126330-AE61AEBA-B991-49C7-9600-ADBD970E3868Q40183925-C8481174-9C06-44CF-874F-56EFA20064B8Q40223648-5215C46F-F6D4-4F5D-BFBB-74D21C9EC872Q40232762-12A9E39E-58BB-49B8-B191-BB52BE9E7F49Q40380718-F147C943-E0A9-44FB-B3DF-25AA8306AAF8Q40383414-B8261E0A-5040-4CB7-8363-55232BA7BA6BQ40949132-45FB55C8-93BA-469D-BC39-5AD94F90A474Q41476310-227CCA16-A9D1-4457-95F3-31FD8B3F4058Q43053201-790027B4-9034-4A87-9E68-F903B40249E7Q43439981-264655FF-BA54-44FF-B810-306DC7D4134AQ44452630-9DE486A9-0F3E-44E7-9BE8-7E45627389C1Q47201744-54F9E750-5525-4ABF-B7A1-B7AF1B620DB1Q47687376-221FDB38-9E35-4BE0-8AE6-6814512B412BQ48065000-C26EBA0D-BC2C-450F-85C6-B16819CF828FQ48515752-D63838ED-3744-48C0-B6D5-905796BFA140Q49593848-D6B30B79-0099-434B-ACC7-CFE1471468B8Q49788662-C9B8CE57-97FB-4501-80A2-5B174D7673D9Q50014474-07BEA24A-E133-432F-A784-5BC22D473C8EQ50016166-3AC55F87-E37B-48B7-8EDD-07DC6A0CF4EDQ50263868-D3D4372B-7AF2-44DB-8029-BADC2F24FC33Q51040534-075B1949-FE19-4E00-A0F5-23DC6B03E36E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter C Lanyon
@ast
Peter C Lanyon
@en
Peter C Lanyon
@es
Peter C Lanyon
@nl
Peter C Lanyon
@sl
type
label
Peter C Lanyon
@ast
Peter C Lanyon
@en
Peter C Lanyon
@es
Peter C Lanyon
@nl
Peter C Lanyon
@sl
prefLabel
Peter C Lanyon
@ast
Peter C Lanyon
@en
Peter C Lanyon
@es
Peter C Lanyon
@nl
Peter C Lanyon
@sl
P106
P21
P31
P496
0000-0002-9855-6802
P569
2000-01-01T00:00:00Z